Other Events ·
On August 25, 2026, Summit Therapeutics announced that partner Akeso reported positive topline results from the Phase…
SMMTSummit Therapeutics Inc.
On August 25, 2026, Summit Therapeutics announced that partner Akeso reported positive topline results from the Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy versus durvalumab plus chemotherapy for first-line advanced biliary tract cancer. The regimen achieved statistically significant and clinically meaningful superiority in overall survival, progression-free survival, and objective response rate. This marks the first known Phase III study in this indication to demonstrate overall survival benefit against an anti-PD-(L)1 plus chemotherapy backbone. Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies.